Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population

PHASE2CompletedINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

May 11, 2005

Primary Completion Date

July 4, 2006

Study Completion Date

July 4, 2006

Conditions
InfluenzaInfluenza Vaccines
Interventions
BIOLOGICAL

SB218352_15

Non-adjuvanted pandemic influenza A formulation 1 vaccine

BIOLOGICAL

SB218352_8

Non-adjuvanted pandemic influenza A formulation 2 vaccine

BIOLOGICAL

SB218352_4

Non-adjuvanted pandemic influenza A formulation 3 vaccine

BIOLOGICAL

SB218352_2

Non-adjuvanted pandemic influenza A formulation 4 vaccine

BIOLOGICAL

SB218352_8AL

Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine

BIOLOGICAL

SB218352_4AL

Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine

BIOLOGICAL

SB218352_2AL

Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine

Trial Locations (10)

14669

GSK Investigational Site, Ketzin

21255

GSK Investigational Site, Tostedt

23795

GSK Investigational Site, Bad Segeberg

24576

GSK Investigational Site, Bad Bramstedt

25335

GSK Investigational Site, Elmshorn

03238

GSK Investigational Site, Finsterwalde

01219

GSK Investigational Site, Dresden

01307

GSK Investigational Site, Dresden

09326

GSK Investigational Site, Geringswalde

01762

GSK Investigational Site, Schmiedeberg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00306995 - Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population | Biotech Hunter | Biotech Hunter